Compare Hinge Health Inc. Class A Common Stock (HNGE) vs JD.Com Inc (JD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs JD.Com Inc — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.47B), while JD.Com Inc trades at $26.71 (market cap $36.93B). The key difference: JD.Com Inc is far larger — about 4.4× Hinge Health Inc. Class A Common Stock's market cap, and JD.Com Inc pays a 3.75% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and JD.Com Inc for 86 Days on average.
| HNGE | JD | |
|---|---|---|
Market Cap | $8.47B | $36.93B |
Volume | 1,624,526 | 6,680,917 |
Sector | Health | Consumer Cyclical |
52-Week High | $105.14 | $34.53 |
52-Week Low | $31.17 | $25.19 |
Typical Hold Time | 0 Days | 86 Days |
Enterprise Value | $8.09B | $19.54B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
JD.com trades at $26.78, up 0.22% on the day, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $0.93 surpassing the $0.86 forecast. Revenue for 2025 reached $1.31 trillion, though net income margin compressed to 1.13%. The company is pursuing growth via acquisitions, such as the pending $2.5 billion Ceconomy deal, which recently gained EU approval momentum (Reuters, 2026-10-02).
The stock appears undervalued with a P/E of 17.78 and P/S of 0.2, well below sector averages. Analyst consensus is strongly bullish with a $35.38 price target, implying ~32% upside. Key risks include regulatory scrutiny in China and Europe, volatile cash flows, and competitive pressures. The robust balance sheet with $234 billion cash provides a margin of safety, but investors must weigh growth initiatives against macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
